Feb. 5, 2021 — The world’s first single-dose COVID-19 vaccine, from Johnson & Johnson, has been submitted to the U.S. Meals and Drug Administration for emergency use approval.
Preliminary findings from a big worldwide research counsel the vaccine is not fairly as robust as the 2 present FDA-approved vaccines from Pfizer and Moderna, that are two-dose vaccines, the Related Press reported.
Nevertheless, the J&J vaccine is simpler to make use of and will ease COVID-19 vaccine shortages.
An FDA advisory panel will assessment knowledge on the brand new vaccine on Feb. 26. The FDA will then resolve whether or not to approve it.
FDA Vaccine Chief Dr. Peter Marks has cautioned towards making comparisons between vaccines earlier than all the proof is collected.
“With a lot must get this pandemic underneath management, I believe we will not ignore any software within the software chest,” he instructed the American Medical Affiliation final week, the AP reported. “We must do our greatest to attempt to be sure that we discover the populations that profit probably the most from every of those vaccines and deploy them in a really considerate method.”
The J&J vaccine was 66% efficient at stopping average to extreme COVID-19, and 85% protecting towards probably the most severe signs, based on early outcomes of the medical trial that included 44,000 individuals in the USA, Latin America and South Africa, the AP reported.
And beginning 28 days after receiving the vaccine, nobody who obtained it required hospitalization or died.